A 2026 target-trial emulation involving 102,361 U.S. veterans with type 2 diabetes found no increased suicidality risk after starting semaglutide vs. sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors): suicidal ideation HR 0.99 and suicide attempt/death HR 1.05 after overlap weighting.1 That does not prove semaglutide prevents suicide, but it weakens the broad claim that semaglutide initiation itself …
GLP-1 drugs are usually described as appetite drugs, but a 2026 Nature mouse study mapped a more specific reward circuit: small-molecule GLP-1 receptor agonists suppressed palatable-food intake through Glp1r-expressing central-amygdala neurons that reduced dopamine release in the nucleus accumbens during high-fat-food retrieval.1 That mechanism makes binge-eating and substance-use hypotheses more plausible without turning an animal …
Semaglutide is not close to being an approved cocaine-use-disorder medication, but a 2026 rat study gives the idea a more demanding preclinical test than ordinary self-administration experiments. After 5 days of treatment, rats shifted away from cocaine choice without losing total operant responding, which separates the result from a broad appetite-suppression artifact. Research Highlights Semaglutide …
A 2026 Scientific Reports paper involving 1,205 participants found that people using GLP-1-style weight-loss medication were judged as less effortful, less moral, less competent, less warm, less deserving, and less attractive as cooperation partners after the same 20 kg weight loss described for a diet-and-exercise-only comparator. Research Highlights Same weight loss, harsher judgment: Tissot et …
Obesity now affects over 650 million adults globally and is a major risk factor for various chronic diseases including cognitive decline and impairment. Recent evidence shows a link between obesity, reduced brain volume and neuronal loss, increased dementia risk, and impaired learning, memory and cognition. Preliminary evidence suggests that weight loss drugs like semaglutide may …